Strongbridge Biopharma plc Added to the Russell 3000® and Microcap® Indexes
01 juil. 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., July 01, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Present at the 2019 JMP Securities Life Sciences Conference
12 juin 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., June 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Strengthens Senior Leadership Team with Key Promotion and Appointment
04 juin 2019 07h30 HE
|
Strongbridge Biopharma plc
Scott Wilhoit Promoted to Chief Commercial Officer Marcy Nanus Appointed Vice President of Corporate Affairs DUBLIN, Ireland and TREVOSE, Pa., June 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge...
Strongbridge Biopharma plc to Present at the Jefferies 2019 Global Healthcare Conference
30 mai 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting
09 mai 2019 16h05 HE
|
Strongbridge Biopharma plc
~ Results Demonstrate Long-term Treatment with KEVEYIS is Efficacious and Provides Durable Reduction in Attack Frequency and Severity in Patients with PPP ~ DUBLIN, Ireland and TREVOSE, Pa., May 09,...
Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update
01 mai 2019 07h30 HE
|
Strongbridge Biopharma plc
~ Following Type C Meeting with the U.S. Food & Drug Administration (FDA), Strongbridge Plans to Submit its New Drug Application (NDA) for RECORLEV™ (levoketoconazole) in the Third Quarter of...
Strongbridge Biopharma plc Announces Presentation of New Secondary Endpoint Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress
25 avr. 2019 16h01 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Host First Quarter 2019 Financial Results Conference Call on May 1, 2019
24 avr. 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., April 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress
15 avr. 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., April 15, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
25 mars 2019 07h30 HE
|
Strongbridge Biopharma plc
~ Subgroup Analysis of Patients with Comorbid Diabetes Mellitus and Cushing’s Syndrome Presented at Annual Meeting of the Endocrine Society (ENDO) Shows Potential Clinical Benefit of Treatment with...